Research-grade BioVector production service
Services offered to accelerate the development of gene therapies:
At the early-stage of development, non-GMP grade rAAV vectors are generally produced using adherent cells. Upon scale-up towards clinical trial testing, the need for GMP grade high titre vectors necessitates a switch to suspension cells for production.
This often results in requirement of re-optimisation of the gene therapy candidate, which can be costly and an inefficient use of time.
Building on our experience of developing gene therapies that are now in clinical trial, our new service removes the need for re-optimisation.
This is because we use suspension cells to produce affordable research-grade vectors for your early proof-of-concept studies. This accelerates the translation of products to clinic, resulting in a saving on development costs overall.
Using high-spec technical equipment, we are removing the need for re-optimisation of gene therapy vectors upon scale-up, whilst enabling affordable and clinically relevant proof-of-concept studies.
Want to learn more about how we can meet your requirements with this service? Contact us on NHC-Operations@tees.ac.uk or fill in the below enquiry form.
Company makes enquiry
We assess the request and come back with a quote approx. 5 working days later along with terms and conditions.
Terms & conditions, quote are accepted. We request materials from customer if required.
QC validation of the sample then into production. Company will be sent interim and final reports of quality checks of products.
Company will be notified of shipping and requirements of conditions for transfer.
VecTUs will store reagents required for repeat manufacture for 1 year.
